Zoledronic Acid (Aclasta, Zerlinda, Zometa)
Comprehensive guide to zoledronic acid for osteoporosis, Paget's disease, cancer bone issues, uses, dosage, and side effects.
Zoledronic acid is a potent bisphosphonate medication administered via intravenous infusion under brand names like Aclasta, Zerlinda, and Zometa. It slows bone breakdown by inhibiting osteoclasts, making it effective for treating osteoporosis, Paget’s disease of bone, and preventing skeletal complications in cancer patients.
About zoledronic acid
Zoledronic acid belongs to the bisphosphonate class, which binds to bone hydroxyapatite and disrupts osteoclast function through inhibition of farnesyl pyrophosphate synthase, leading to reduced bone resorption and stronger bones. It is particularly useful for patients unable to take oral bisphosphonates due to gastrointestinal issues or for those needing rapid action. Unlike oral forms, it is given once yearly for osteoporosis or every 3-4 weeks for cancer-related uses, improving adherence.
The drug accumulates in bone, where acidification during resorption releases it into osteoclasts, triggering apoptosis via disrupted protein prenylation. This mechanism strengthens bone density and reduces fracture risk in high-risk groups.
Key facts about zoledronic acid
- Drug group: Bisphosphonate (inhibits bone-resorbing osteoclasts).
- Brand names: Aclasta (osteoporosis/Paget’s), Zometa (cancer/hypercalcemia), Zerlinda (similar to Aclasta).
- Administration: Intravenous infusion over at least 15 minutes once yearly for osteoporosis; more frequent for cancer.
- Common uses: Postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, Paget’s disease, bone metastases, hypercalcemia of malignancy.
- Dose for osteoporosis: 5 mg once per year; requires calcium/vitamin D supplementation.
- Not suitable for: Severe kidney impairment (CrCl <35 mL/min), hypocalcemia, pregnancy.
When is zoledronic acid prescribed?
Zoledronic acid is prescribed for conditions involving excessive bone loss or high fracture risk. Primary indications include:
- Osteoporosis: In postmenopausal women and men at increased fracture risk, especially post-hip fracture. It reduces hip fractures by 41% vs placebo in studies (9% vs 13% fracture rate).
- Glucocorticoid-induced osteoporosis: For patients on long-term steroids, superior to risedronate in increasing spine bone density.
- Paget’s disease: Normalizes serum alkaline phosphatase in 85-96% of patients vs 74% with risedronate after 6 months.
- Cancer-related: Prevents bone complications in multiple myeloma, solid tumor metastases; treats tumor-induced hypercalcemia.
In breast cancer, it may reduce recurrence risk when given with aromatase inhibitors.
Dosage
Dosage varies by indication:
| Indication | Dose | Frequency | Infusion Time |
|---|---|---|---|
| Osteoporosis (Aclasta/Zerlinda) | 5 mg | Once yearly | At least 15 min |
| Paget’s disease | 5 mg | Single dose | At least 15 min |
| Hypercalcemia (Zometa) | 4 mg | Single dose | At least 15 min |
| Bone metastases/Myeloma (Zometa) | 4 mg | Every 3-4 weeks | No less than 15 min |
Adjust for renal function: Omit if CrCl <35 mL/min for Aclasta; <30 mL/min for Zometa. Premedicate with acetaminophen/paracetamol for flu-like symptoms; ensure calcium >2 mg/dL and supplement 1500 mg calcium + 1150 mcg vitamin D daily.
How and when to take it
Zoledronic acid is given by healthcare professionals via IV drip into a vein, typically over 15+ minutes to minimize renal risk. For osteoporosis, infuse after morning hydration; avoid same-day dental work. Patients should hydrate well pre-infusion and take supplements as directed. No food restrictions, but dental check-ups are advised before starting due to osteonecrosis risk.
Common questions about zoledronic acid
How long does it take to work?
Bone turnover markers decrease within days; peak density effects seen at 1 year. Fracture risk reduction evident in 6-12 months.
Will I have side effects after the infusion?
Acute phase reactions (fever, myalgia, flu-like) occur in 20-30% post-first dose, resolving in 3 days. Less common subsequently.
Can I drive or work after?
Yes, unless side effects like dizziness occur. Rest if flu-like symptoms appear.
Side effects of zoledronic acid
Most are mild/transient; serious risks include ONJ, atypical fractures, renal failure.
Serious side effects
- Osteonecrosis of jaw (ONJ): Rare (0.01-0.04%), higher with cancer dosing/dental issues. Symptoms: jaw pain, swelling, exposed bone.
- Atypical femoral fractures: Long-term use (>3 years); thigh/groin pain signals risk.
- Renal impairment: Monitor CrCl; slow infusion prevents.
- Hypocalcemia: Monitor electrolytes; supplement.
- Atrial fibrillation: Slight increased risk in osteoporosis trials.
Common side effects
- Acute (post-infusion): Fever (18%), headache (11%), myalgia (8%), arthralgia (6%), pain (5%).
- GI: Nausea (9%), vomiting (5%), diarrhea/constipation.
- Other: Fatigue, anemia, bone pain, flu symptoms, dizziness, edema.
Report persistent symptoms or new pains promptly.
How to cope with side effects
- Flu-like symptoms: Paracetamol/ibuprofen; rest, fluids.
- Bone/muscle pain: Analgesics; exercise gently.
- ONJ prevention: Good dental hygiene; pre-treatment check.
- Hypocalcemia: Calcium-rich diet, supplements.
- Renal monitoring: Hydrate; follow blood tests.
Pregnancy and breastfeeding
Contraindicated in pregnancy (Category D; fetal harm risk) and breastfeeding (excreted in milk). Use contraception during/after treatment.
Cautions of zoledronic acid
- Avoid in severe renal impairment, hypocalcemia, hypersensitivity.
- Monitor renal function, calcium, phosphate pre/post-dose.
- Dental precautions for invasive procedures.
- Asthma patients: Rare bronchoconstriction.
- Long-term: Assess atypical fracture/ONJ risk after 3 years.
Interactions
- Nephrotoxic drugs: Aminoglycosides, loop diuretics increase renal risk.
- Calcium-lowering agents: Enhanced hypocalcemia.
- NSAIDs: Caution in acute phase.
- No major food interactions; consistent calcium intake advised.
Alternatives to zoledronic acid
| Drug | Use | Route | Notes |
|---|---|---|---|
| Alendronate, Risedronate | Osteoporosis | Oral | Weekly; GI side effects common. |
| Denosumab (Prolia) | Osteoporosis | SC injection | 6-monthly; hypocalcemia risk. |
| Pamidronate | Hypercalcemia/Cancer | IV | Less potent than zoledronic. |
Frequently Asked Questions (FAQs)
What is the main difference between Aclasta and Zometa?
Aclasta (5 mg yearly) treats osteoporosis/Paget’s; Zometa (4 mg every 3-4 weeks) for cancer bone issues/hypercalcemia.
Does zoledronic acid cause hair loss?
Not commonly reported; rare alopecia in <1%.
Can I take zoledronic acid if I have kidney problems?
No, if CrCl <35 mL/min; monitor closely otherwise.
How long should I take zoledronic acid for osteoporosis?
Typically 3-5 years; reassess ‘drug holiday’ risk.
Is zoledronic acid better than oral bisphosphonates?
Higher adherence, potency; superior fracture reduction in some trials.
References
- Aclasta | European Medicines Agency (EMA) — EMA. 2023-05-15. https://www.ema.europa.eu/en/medicines/human/EPAR/aclasta
- Zoledronic acid: Uses, Interactions, Mechanism of Action | DrugBank — DrugBank. 2024-01-10. https://go.drugbank.com/drugs/DB00399
- Details for: ACLASTA – Drug and Health Product Register — Health Canada. 2023-11-20. https://hpr-rps.hres.ca/details.php?drugproductid=4012
- Zoledronic acid (Zometa) – Cancer Research UK — Cancer Research UK. 2024-02-05. https://www.cancerresearchuk.org/about-cancer/treatment/drugs/zoledronic-acid
- Zoledronic acid (intravenous route) – Mayo Clinic — Mayo Clinic. 2023-12-01. https://www.mayoclinic.org/drugs-supplements/zoledronic-acid-intravenous-route/description/drg-20066951
Similar Articles
Read full bio of medha deb
